SK Biopharmaceuticals Co., Ltd.
326030.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.69T
Close$
$-46634.50
166% downside
Current Fair Value
166% downsideOvervalued by 166% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.69 Trillion |
|---|---|
| Enterprise Value | $5.37 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3408.75 |
| Beta | 0.72 |
| Outstanding Shares | 78,313,000 |
Return
| Return on Equity | 39.24% |
|---|---|
| Return on Assets | 28.26% |
| Return on Invested Capital | 20.09% |
Valuation & Multiples
| P/E Ratio | 14.7 |
|---|---|
| PEG | 9.28 |
| Price to Sales | 6.43 |
| Price to Book Ratio | 5.42 |
| Enterprise Value to Revenue | 6.24 |
| Enterprise Value to EBIT | 24.42 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$563.67
Average shareholder expectationRevenue Estimate
$242.74 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$776.00
Average shareholder expectationRevenue Estimate
$251.13 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SK Biopharmaceuticals Co., Ltd.
241 employees
CEO: Dong Hoon Lee SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicat...